Nimodipine

The standard adult dosage for nimodipine in the treatment of subarachnoid hemorrhage (SAH) is highly standardized to ensure constant therapeutic levels. The typical regimen is 60 mg (two 30 mg capsules or 20 mL of oral solution) administered every 4 hours. This dosing schedule must be maintained consistently for 21 consecutive days. Therapy should ideally begin within 96 hours of the onset of the hemorrhage. If the patient's blood pressure drops significantly, the healthcare provider may adjust the dose or the frequency, but the 60 mg q4h (every 4 hours) remains the clinical benchmark for efficacy.

Nimodipine is not currently FDA-approved for use in pediatric patients. The safety and effectiveness of this medication in children under the age of 18 have not been established. In rare, life-threatening circumstances, pediatric neurosurgeons may use nimodipine off-label, but there is no standardized weight-based dosing guide available for the general public. Any use in children must be strictly managed by a specialist.

Renal Impairment

Specific dosage adjustments for patients with renal (kidney) impairment are generally not required, as nimodipine is primarily metabolized by the liver. However, because the metabolites are excreted via the kidneys, patients with severe renal failure should be monitored closely for any unexpected side effects.

Hepatic Impairment

Patients with hepatic (liver) impairment, such as cirrhosis, require significant dosage adjustments. Because the liver is responsible for breaking down nimodipine, impaired function can lead to dangerously high levels of the drug in the blood. In patients with severe hepatic dysfunction, the dose is typically reduced to 30 mg every 4 hours, and blood pressure must be monitored with extreme vigilance.

Elderly Patients

Geriatric patients may be more sensitive to the hypotensive (blood pressure lowering) effects of nimodipine. While the starting dose is often the same as in younger adults, healthcare providers may monitor elderly patients more frequently for signs of lightheadedness, fainting, or kidney strain due to low blood pressure.

Nimodipine must be taken exactly as prescribed, typically around the clock (e.g., 12 AM, 4 AM, 8 AM, 12 PM, 4 PM, 8 PM).

• With or Without Food: Nimodipine should ideally be taken on an empty stomach, at least 1 hour before or 2 hours after a meal. As noted in the pharmacology section, food—especially high-fat meals—can significantly reduce the amount of drug that enters the bloodstream.
• Swallowing Capsules: Capsules must be swallowed whole. They should never be crushed, chewed, or dissolved in water.
• Administration via Feeding Tube: If a patient cannot swallow, the healthcare provider may use the oral solution. If only capsules are available, the liquid inside the capsule may be extracted with a syringe and administered through a nasogastric (NG) tube. CRITICAL WARNING: This liquid must NEVER be injected into a vein. It must be labeled clearly for oral or enteral use only.
• Storage: Store nimodipine at room temperature (20°C to 25°C or 68°F to 77°F), away from light and moisture. The capsules are light-sensitive and are usually provided in blister packs or dark containers.

If a dose of nimodipine is missed, it should be taken as soon as possible. However, if it is almost time for the next scheduled dose (within 1-2 hours), the missed dose should be skipped. Patients should never 'double up' on doses to make up for a missed one. Maintaining a consistent 4-hour interval is vital for preventing the cerebral vasospasm that the drug is intended to treat.

An overdose of nimodipine is a medical emergency. Symptoms of overdose are primarily related to excessive vasodilation and may include:

• Severe hypotension (dangerously low blood pressure)
• Tachycardia (rapid heartbeat) or Bradycardia (slow heartbeat)
• Nausea and gastrointestinal distress
• Dizziness or loss of consciousness

In the event of a suspected overdose, contact emergency services (911 in the U.S.) or a poison control center immediately. Treatment typically involves supportive care, intravenous fluids to raise blood pressure, and potentially the use of vasopressors (medications that constrict blood vessels).

> Important: Follow your healthcare provider's dosing instructions. Do not adjust your dose without medical guidance. The timing of nimodipine is critical to its success in preventing brain injury.

The most frequently reported side effect of nimodipine is hypotension (low blood pressure). Because nimodipine is a vasodilator, it relaxes blood vessels throughout the body, not just in the brain.

• Hypotension: This may manifest as a feeling of lightheadedness, warmth, or mild dizziness. In a clinical setting, healthcare providers will monitor blood pressure every hour. If the systolic blood pressure drops below 90 mmHg, the dose may need to be held or reduced.
• Headache: Some patients report a 'throbbing' headache shortly after taking the medication, which is common with many calcium channel blockers as they dilate vessels in the scalp and brain.

• Gastrointestinal Issues: Nausea, abdominal discomfort, and occasionally diarrhea or constipation have been reported. These are generally mild and do not require discontinuation of the drug.
• Heart Rate Changes: While some patients experience a compensatory increase in heart rate (tachycardia) due to low blood pressure, others may experience a slowing of the heart rate (bradycardia).
• Skin Rash: A mild allergic-type rash or dermatitis may occur in some individuals.
• Edema: Swelling of the lower extremities (ankles and feet) is a known class effect of dihydropyridine calcium channel blockers, though it is less common with nimodipine than with amlodipine due to the short duration of nimodipine therapy (21 days).

• Hepatotoxicity: Rare cases of elevated liver enzymes (ALT, AST) and jaundice have been noted. This is more likely in patients with pre-existing liver disease.
• Muscle Cramps: Some patients may experience involuntary muscle contractions or 'charley horses.'
• Depression: Rare reports of mood changes or depressive symptoms have been associated with long-term calcium channel blocker use, though this is infrequent in the acute 21-day SAH treatment window.
• Disseminated Intravascular Coagulation (DIC): Extremely rare reports of blood clotting abnormalities have been documented in clinical trials, though a direct causal link is not always established.

> Warning: Stop taking Nimodipine and call your doctor immediately if you experience any of these.

• Severe Hypotension: If you feel like you are going to faint, or if you feel extremely weak and cold, your blood pressure may have dropped to a dangerous level.
• Anaphylaxis: Signs of a severe allergic reaction include hives, difficulty breathing, and swelling of the face, lips, tongue, or throat.
• Congestive Heart Failure: While rare, the negative inotropic effect (weakening of the heart's contraction) can worsen heart failure, leading to shortness of breath and rapid weight gain from fluid retention.
• Intestinal Obstruction: In rare cases, the relaxation of smooth muscle can affect the bowels, leading to a condition called paralytic ileus, where the intestines stop moving. Symptoms include severe bloating, inability to pass gas, and vomiting.

Nimodipine is intended for short-term use (21 days). Consequently, there is limited data on the long-term side effects of this specific drug. However, chronic use of other drugs in this class can lead to gingival hyperplasia (overgrowth of the gums) and persistent peripheral edema. Because nimodipine is used in a critical care context, the focus is on acute management rather than long-term maintenance.

WARNING: NOT FOR INTRAVENOUS ADMINISTRATION

Nimodipine has a critical FDA Black Box Warning regarding its administration. There have been numerous reports of death and life-threatening cardiovascular events when the liquid contents of nimodipine capsules were accidentally injected intravenously (into a vein).

• The Danger: When nimodipine is injected directly into the bloodstream, it causes a catastrophic drop in blood pressure, leading to cardiac arrest and death.
• Prevention: Nimodipine must ONLY be administered orally or through a feeding tube (enteral). Healthcare providers are instructed to use a syringe that cannot be connected to an IV line when withdrawing the liquid from a capsule for NG tube administration. The FDA-approved oral solution (Nymalize) was specifically developed to help prevent these tragic errors.

Report any unusual symptoms to your healthcare provider. Monitoring in an Intensive Care Unit (ICU) is standard for patients receiving this medication.

Nimodipine is a high-alert medication that must be managed by healthcare professionals in a hospital setting. The most important safety consideration is the prevention of administration errors. Patients and caregivers must be aware that this medication is never to be given by any route other than the mouth or a feeding tube. Furthermore, because nimodipine affects the cardiovascular system, it must be used with caution in patients with unstable heart conditions or those taking other medications that lower blood pressure.

DO NOT ADMINISTER NIMODIPINE INTRAVENOUSLY OR BY OTHER PARENTERAL ROUTES.

Deaths and serious, life-threatening adverse events, including cardiac arrest, severe hypotension, and cardiovascular collapse, have occurred when the contents of nimodipine capsules have been injected intravenously. If nimodipine is extracted from a capsule for administration via a feeding tube, it must be administered using a syringe specifically labeled 'Not for IV Use.' The use of the oral solution formulation is preferred to minimize the risk of administration errors.

• Allergic Reactions: While rare, hypersensitivity to nimodipine or any components of the capsule/solution can occur. Patients with a known allergy to other calcium channel blockers (like nifedipine) should use nimodipine with caution due to the risk of cross-sensitivity.
• Hepatic Impairment: Since nimodipine is metabolized by the liver, patients with cirrhosis or hepatitis are at a much higher risk of toxicity. The drug can accumulate in the body, leading to profound hypotension. Dose reductions are mandatory in these populations.
• Cardiovascular Risk: Nimodipine should be used with caution in patients with a history of heart failure or significant left ventricular dysfunction, as calcium channel blockers can slightly reduce the strength of the heart's contraction.
• Intracranial Pressure: While nimodipine is used for brain-related bleeding, some studies suggest it may cause a slight increase in intracranial pressure in certain patients. Close monitoring of neurological status is required.

Patients taking nimodipine require frequent and intensive monitoring:

• Blood Pressure: Often monitored hourly during the initial phase of treatment. If systolic blood pressure falls below 90 mmHg, the medication may be paused.
• Heart Rate: Monitored for signs of bradycardia or reflex tachycardia.
• Liver Function Tests (LFTs): Baseline and periodic liver enzymes may be checked, especially in patients with known liver issues.
• Neurological Exams: Frequent 'neuro checks' are performed to assess if the medication is effectively preventing ischemic deficits or if the patient's condition is deteriorating.

Nimodipine can cause dizziness, lightheadedness, and low blood pressure. Patients receiving nimodipine for subarachnoid hemorrhage are typically hospitalized and not in a condition to drive. However, if used in an outpatient setting for off-label purposes, patients should not drive or operate heavy machinery until they know how the medication affects them.

Alcohol should be strictly avoided while taking nimodipine. Alcohol acts as a vasodilator and can significantly enhance the blood pressure-lowering effects of nimodipine, leading to a high risk of fainting, severe hypotension, and injury.

Nimodipine is typically taken for exactly 21 days. There is no evidence of a 'withdrawal syndrome' or a need for tapering when stopping the drug after the 21-day course. However, the medication should never be stopped early unless directed by a physician, as the risk of cerebral vasospasm remains high for several weeks following a subarachnoid hemorrhage.

> Important: Discuss all your medical conditions, especially liver disease or heart problems, with your healthcare provider before starting Nimodipine.

Nimodipine is primarily metabolized by the CYP3A4 enzyme. Therefore, the use of strong CYP3A4 inducers is strictly contraindicated, as they can reduce nimodipine levels in the blood to the point where the drug becomes completely ineffective. Examples include:

• Rifampin: An antibiotic used for tuberculosis.
• Phenytoin and Carbamazepine: Medications used for seizures.
• Phenobarbital: A sedative and anti-seizure medication.
• St. John's Wort: An herbal supplement for depression.

Using these together can lead to a failure of therapy, increasing the risk of permanent brain damage from vasospasm.

Conversely, strong CYP3A4 inhibitors can cause nimodipine levels to skyrocket, leading to dangerous hypotension. If these must be used, the nimodipine dose may need to be reduced, and blood pressure must be monitored constantly. Examples include:

• Ketoconazole and Itraconazole: Antifungal medications.
• Ritonavir and Indinavir: HIV protease inhibitors.
• Clarithromycin and Telithromycin: Macrolide antibiotics.
• Nefazodone: An antidepressant.

• Other Calcium Channel Blockers: Taking nimodipine with amlodipine, nifedipine, or verapamil can have an additive effect on blood pressure and heart rate.
• Antihypertensives: Beta-blockers (like metoprolol), ACE inhibitors (like lisinopril), and diuretics can all increase the risk of severe low blood pressure when combined with nimodipine.
• Valproic Acid: This seizure medication may increase the plasma concentration of nimodipine through enzyme inhibition.

• Grapefruit and Grapefruit Juice: This is a critical interaction. Grapefruit contains compounds that inhibit the CYP3A4 enzyme in the gut. Drinking grapefruit juice while taking nimodipine can increase the drug's bioavailability by up to 2-fold, leading to unpredictable and potentially dangerous drops in blood pressure. Grapefruit should be completely avoided during the 21-day treatment course.
• High-Fat Meals: As previously mentioned, high-fat food can decrease the absorption of nimodipine. It is best taken on an empty stomach.

• St. John's Wort: As a potent inducer of CYP3A4, this herb can significantly lower nimodipine levels and should be avoided.
• Ginkgo Biloba and Garlic: These supplements may have mild blood-thinning or vasodilatory effects that could theoretically interact with the management of a patient recovering from a brain bleed, though data is limited.
• Melatonin: Some studies suggest melatonin may interact with calcium channel blockers, potentially affecting blood pressure control.

Nimodipine is not known to significantly interfere with most common laboratory tests (such as basic metabolic panels or complete blood counts). However, it may occasionally cause a false elevation in liver function tests due to its metabolic pathway. Always inform the laboratory and your physicians of all medications you are taking.

> Important: Tell your doctor about ALL medications, supplements, and herbal products you are taking. A complete list is essential to prevent dangerous interactions during your recovery.

Nimodipine must NEVER be used in the following circumstances:

• Hypersensitivity: Patients with a known severe allergy to nimodipine or any of the inactive ingredients (such as gelatin or glycerin in the capsules) must not take the drug. Anaphylaxis is a risk.
• Concomitant use of Strong CYP3A4 Inducers: As discussed in the interactions section, drugs like rifampin, phenytoin, and carbamazepine make nimodipine ineffective. Using them together is considered an absolute contraindication because it leaves the patient's brain unprotected from vasospasm.
• Intravenous Administration: This is a contraindication of route. Nimodipine must never be given via IV due to the risk of immediate death.

In some cases, the benefits of nimodipine may outweigh the risks, but extreme caution is required:

• Severe Hepatic Impairment: Patients with Child-Pugh Class C cirrhosis have a greatly reduced ability to clear the drug. While not an absolute contraindication, it requires a 50% dose reduction and constant monitoring.
• Severe Hypotension: If a patient already has a systolic blood pressure below 90 mmHg, starting nimodipine may be delayed until the patient is stabilized with fluids or pressors.
• Acute Myocardial Infarction: During the early stages of a heart attack, the use of short-acting dihydropyridines can be risky due to reflex tachycardia and increased oxygen demand on the heart.

Patients who have had a severe adverse reaction to other dihydropyridine calcium channel blockers (such as nifedipine, felodipine, or nicardipine) may be at an increased risk of a similar reaction to nimodipine. While they are chemically distinct, their shared structure means that a patient who experienced angioedema (severe swelling) with one may experience it with the other.

> Important: Your healthcare provider will evaluate your complete medical history, including liver function and current medications, before prescribing Nimodipine. This assessment is vital for your safety.

Nimodipine is classified as Pregnancy Category C. This means that animal reproduction studies have shown an adverse effect on the fetus (such as skeletal abnormalities and stunted growth), but there are no adequate and well-controlled studies in humans. Nimodipine should be used during pregnancy only if the potential benefit to the mother justifies the potential risk to the fetus. In the case of a life-threatening subarachnoid hemorrhage, the mother's survival and neurological health are prioritized, but the medical team must be aware of the potential teratogenic risks.

Studies have shown that nimodipine and its metabolites are excreted in rat milk. While there is limited data on human breast milk, it is generally assumed that nimodipine will pass into the milk. Because of the potential for serious adverse reactions in nursing infants (such as low blood pressure), a decision should be made whether to discontinue nursing or discontinue the drug, taking into account the importance of the drug to the mother. Most experts recommend against breastfeeding while taking nimodipine.

The safety and effectiveness of nimodipine in pediatric patients have not been established. There is no FDA-approved dosing for children. While some pediatric neurosurgeons may use it in rare cases of childhood stroke or hemorrhage, this is done with extreme caution and without the support of large-scale clinical trials.

Clinical studies of nimodipine did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. However, in general, elderly patients are more likely to have decreased hepatic or renal function and may be taking multiple other medications (polypharmacy). This increases the risk of drug interactions and severe hypotension. In older adults, blood pressure and kidney function should be monitored more frequently, and the risk of falls due to dizziness must be managed.

While the kidneys are not the primary route of nimodipine metabolism, they are responsible for excreting the inactive metabolites. In patients with significant renal impairment (GFR < 30 mL/min), there is a theoretical risk of metabolite accumulation. However, no specific dose adjustment is currently recommended by the FDA for renal failure. Monitoring of fluid balance and blood pressure is sufficient.

This is the most critical special population for nimodipine. Hepatic impairment (liver disease) significantly increases the 'area under the curve' (AUC) and peak plasma concentration (Cmax) of nimodipine.

• Mild to Moderate Impairment: Use with caution; monitor blood pressure closely.
• Severe Impairment (Cirrhosis): The dose should be reduced to 30 mg every 4 hours. Failure to adjust the dose can lead to life-threatening hypotension.

> Important: Special populations require individualized medical assessment. Always inform your doctor if you are pregnant, planning to become pregnant, or have a history of liver disease.

Nimodipine is a 1,4-dihydropyridine calcium channel blocker. It acts by binding to L-type (long-lasting) voltage-gated calcium channels in the membranes of vascular smooth muscle and neurons. By inhibiting the transmembrane influx of calcium ions, nimodipine prevents the calcium-dependent contraction of arterial smooth muscle. Its specific efficacy in subarachnoid hemorrhage is attributed to its high lipophilicity, which allows it to cross the blood-brain barrier and target cerebral arteries more effectively than other drugs in its class. It prevents the delayed cerebral ischemia (DCI) that typically occurs 4 to 14 days after a brain bleed.

The primary pharmacodynamic effect of nimodipine is vasodilation, particularly in the cerebral vasculature. In humans, nimodipine increases cerebral blood flow and reduces the resistance of brain vessels. It has a minimal effect on the heart's conduction system (unlike verapamil or diltiazem) but can cause a decrease in systemic vascular resistance, leading to a drop in blood pressure. The onset of action is rapid (within 1 hour), and the duration of effect is relatively short, which is why it requires dosing every 4 hours.

| Parameter | Value |

|---|---|

| Bioavailability | ~13% (Extensive first-pass metabolism) |

| Protein Binding | >95% (Primarily to albumin) |

| Half-life | 8-9 hours (Terminal); 1-2 hours (Initial) |

| Tmax | 1 hour |

| Metabolism | Hepatic (CYP3A4) |

| Excretion | Renal (50% as metabolites), Fecal (32%) |

• Molecular Formula: C21H26N2O7
• Molecular Weight: 418.44 g/mol
• Solubility: Practically insoluble in water; highly soluble in lipids and organic solvents.
• Structure: Nimodipine is a yellow crystalline powder. It is a racemic mixture of two enantiomers, both of which contribute to its pharmacological activity.

Nimodipine is classified as a Dihydropyridine Calcium Channel Blocker [EPC]. Other medications in this class include nifedipine, amlodipine, and nicardipine. However, nimodipine is the only member of this class specifically indicated for the management of subarachnoid hemorrhage due to its unique ability to penetrate the central nervous system.